Therapeutic strategies for congenital myasthenic syndromes
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS...
Asıl Yazarlar: | Lee, M, Beeson, D, Palace, J |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
Wiley
2018
|
Benzer Materyaller
-
The congenital myasthenic syndromes.
Yazar:: Palace, J, ve diğerleri
Baskı/Yayın Bilgisi: (2008) -
Congenital myasthenic syndromes.
Yazar:: Beeson, D, ve diğerleri
Baskı/Yayın Bilgisi: (1997) -
Congenital myasthenic syndromes: an update.
Yazar:: Finlayson, S, ve diğerleri
Baskı/Yayın Bilgisi: (2013) -
Congenital myasthenic syndromes and the neuromuscular junction.
Yazar:: Cruz, P, ve diğerleri
Baskı/Yayın Bilgisi: (2014) -
The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes
Yazar:: Rodríguez Cruz, P, ve diğerleri
Baskı/Yayın Bilgisi: (2018)